Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis
- Marks start of European commercial rollout of aXess™, bringing it into routine clinical practice
- Builds on CE mark approval in record time, underpinned by positive EU pivotal trial data
- Introduces a first-of-its-kind living vascular access solution for patients requiring hemodialysis
EINDHOVEN, The Netherlands – 7 July, 2026 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announced today the official start of the European commercialization of aXess™, marked by the successful treatment of the first commercial patient by Dr Dominik Liebetrau at Artemed Klinikum Munich South, Germany.
